GADD45&#945;-targeted suicide gene therapy driven by synthetic CArG promoter E9NS sensitizes NSCLC cells to cisplatin, resveratrol, and radiation regardless of p53 status.

Shi, Qiwen; Sutariya, Vijaykumar; Varghese Gupta, Sheeba; Bhatia, Deepak

GADD45α-targeted suicide gene therapy driven by synthetic CArG promoter E9NS sensitizes NSCLC cells to cisplatin, resveratrol, and radiation regardless of p53 status.

Shi, Qiwen; Sutariya, Vijaykumar; Varghese Gupta, Sheeba; Bhatia, Deepak.

Afiliação

Shi Q; Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, Zhejiang, People's Republic of China.
Sutariya V; College of Pharmacy, University of South Florida, Tampa, FL, USA.
Varghese Gupta S; College of Pharmacy, University of South Florida, Tampa, FL, USA.
Bhatia D; Bernard J. Dunn School of Pharmacy, Shenandoah University, Ashburn, VA, USA.

Onco Targets Ther ; 12: 3161-3170, 2019.

Article em En | MEDLINE | ID: mdl-31114253